FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
14.1 USD
-0.05 (-0.355%)
INBX Financial Statements
Quarter
2024 Q3
2024 Q2
2024 Q1
2023 Q4
Total Revenue
0
100k
0
1.63M
Cost of Revenue
0
475k
360k
298k
Gross Profit
0
-375k
-360k
1.34M
Operating Expenses
46.8M
161M
73.47M
89.63M
Research and Development
38.89M
67.63M
63.59M
81.84M
Selling, General & Administrative Expenses
7.9M
93.37M
9.87M
7.79M
Selling & Marketing Expenses
0
0
-104k
-46k
General & Administrative Expenses
7.9M
93.37M
9.97M
7.83M
Other Expenses
0
0
-59k
-158k
Operating Income
-46.8M
-160.9M
-73.83M
-88.29M
Total Other Income/Expenses Net
2.93M
2.02B
-4.88M
-3.69M
Income Before Tax
-43.86M
1.86B
-78.71M
-91.97M
Income Tax
0
2k
316.72k
-4k
Net Income
-43.86M
1.86B
-78.71M
-93.6M
Basic EPS
-2.84
128.35
-1.44
-1.73
EPS Diluted
-2.84
125.48
-1.44
-1.73
Basic Average Shares
15.47M
14.48M
54.55M
54.03M
Diluted Average Shares
15.47M
14.81M
54.55M
54.03M
EBITDA
-46.8M
1.86B
-73.47M
-87.99M
Retained Earning Schedule
Quarter
2024 Q3
2024 Q2
2024 Q1
2023 Q4
Retained Earnings (Previous Year)
-14.4M
-692.44M
-613.73M
-520.13M
Net Income
-43.86M
1.86B
-78.71M
-93.6M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-58.27M
-14.4M
-692.44M
-613.73M
Other Distributions
-43.86M
678.04M
-78.71M
-93.6M
PPE Schedule
Quarter
2024 Q3
2024 Q2
2024 Q1
2023 Q4
Gross PPE
8.4M
9.62M
9.45M
9.37M
Annual Depreciation
760k
476k
360k
298k
Capital Expenditure
-247k
-1.22M
-1.12M
-3.44M
Net PPE
7.89M
10.36M
10.21M
12.52M
Intangible and Goodwill Schedule
Quarter
2024 Q3
2024 Q2
2024 Q1
2023 Q4
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
